Literature DB >> 26233681

Influence of menopausal status on diagnostic accuracy of myometrial invasion in endometrial cancer: diffusion-weighted and dynamic contrast-enhanced MRI at 3 T.

G Lin1, Y-T Huang1, A Chao2, K-K Ng1, L-Y Yang3, S-H Ng4, C-H Lai2.   

Abstract

AIM: To assess the influence of menopausal status on the diagnostic accuracy of diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for evaluating myometrial invasion in patients diagnosed with endometrial cancer.
MATERIALS AND METHODS: In this prospective study, 91 consecutive female patients diagnosed with endometrial cancer were enrolled for preoperative evaluation using 3 T MRI. Two radiologists interpreted myometrial invasion depth on DW (b=1000 s/mm(2)) and DCE MRI images, with surgical histopathology as the reference standard. Statistical methods included kappa statistics for evaluating reader agreement and diagnostic performance analysis between pre- and postmenopausal groups.
RESULTS: Reader agreement of DW MRI was poor (κ=0.20) for premenopausal patients. The diagnostic accuracy of DW MRI in detecting myometrial involvement was significantly lower in premenopausal compared with postmenopausal patients (0.42 versus 0.73, p=0.006). There was no difference in the diagnostic accuracy of DW MRI in detecting deep myometrial invasion between premenopausal and postmenopausal groups (0.94 versus 0.95, p>0.99).
CONCLUSION: For premenopausal patients who plan to receive fertility-preserving treatment for endometrial cancer, DCE MRI is superior to DW MRI in excluding any possible myometrial invasion. For preoperative assessment of deep myometrial invasion, DW MRI can be a legitimate alternative to DCE MRI regardless of menopausal status and is particularly beneficial for patients at risk of nephrogenic systemic fibrosis.
Copyright © 2015 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26233681     DOI: 10.1016/j.crad.2015.06.097

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  6 in total

1.  Endometrial cancer with cervical stromal invasion: diagnostic accuracy of diffusion-weighted and dynamic contrast enhanced MR imaging at 3T.

Authors:  Gigin Lin; Yu-Ting Huang; Angel Chao; Yu-Chun Lin; Lan-Yan Yang; Ren-Chin Wu; Hsin-Ying Lu; Shu-Hang Ng; Koon-Kwan Ng; Chyong-Huey Lai
Journal:  Eur Radiol       Date:  2016-09-09       Impact factor: 5.315

2.  Preoperative staging of endometrial cancer using reduced field-of-view diffusion-weighted imaging: a preliminary study.

Authors:  Takashi Ota; Masatoshi Hori; Hiromitsu Onishi; Makoto Sakane; Takahiro Tsuboyama; Mitsuaki Tatsumi; Atsushi Nakamoto; Tadashi Kimura; Yoshifumi Narumi; Noriyuki Tomiyama
Journal:  Eur Radiol       Date:  2017-07-03       Impact factor: 5.315

3.  Multiparametric magnetic resonance imaging facilitates the selection of patients prior to fertility-sparing management of endometrial cancer.

Authors:  Yuki Himoto; Yulia Lakhman; Shinya Fujii; Satoshi Morita; Jennifer J Mueller; Mario M Leitao; Aki Kido
Journal:  Abdom Radiol (NY)       Date:  2021-04-07

Review 4.  Current Status of Magnetic Resonance Imaging in Patients with Malignant Uterine Neoplasms: A Review.

Authors:  Yu-Ting Huang; Yen-Ling Huang; Koon-Kwan Ng; Gigin Lin
Journal:  Korean J Radiol       Date:  2018-12-27       Impact factor: 3.500

5.  Endometrial carcinoma: use of tracer kinetic modeling of dynamic contrast-enhanced MRI for preoperative risk assessment.

Authors:  Zhijun Ye; Gang Ning; Xuesheng Li; Tong San Koh; Huizhu Chen; Wanjing Bai; Haibo Qu
Journal:  Cancer Imaging       Date:  2022-03-09       Impact factor: 3.909

6.  Peritumoral Enhancement for the Evaluation of Myometrial Invasion in Low-Risk Endometrial Carcinoma on Dynamic Contrast-Enhanced MRI.

Authors:  Tingting Cui; Feng Shi; Bei Gu; Yanfang Jin; Jinsong Guo; Chao Zhang; Jie Ren; Yunlong Yue
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.